Results 61 to 70 of about 32,925 (256)
British Journal of Clinical Pharmacology, EarlyView.Improvement in medication adherence is often proposed as a potential advantage of pharmacogenetic‐guided prescribing over a traditional one‐size‐fits‐all approach. This paper provides a review of the published literature and presents the findings of studies that measure adherence to medication as an outcome of pharmacogenetic‐informed care, or that ...
Lucy Galloway +2 more
wiley +1 more source
Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice [PDF]
Molecular Pharmacology, 2015 Cholestasis activates bile acid receptor farnesoid X receptor (FXR) and subsequently enhances hepatic expression of small heterodimer partner (SHP). We previously demonstrated that SHP represses the transactivation of cytochrome P450 2D6 (CYP2D6) promoter by hepatocyte nuclear factor (HNF) 4α.
Xian, Pan, Hyunyoung, Jeong
openaire +2 more sources
Pharmacogenomics and Personalized Medicine, 2020 Benjamin Q Duong,1 Meghan J Arwood,2 J Kevin Hicks,3 Amber L Beitelshees,4 Francesco Franchi,5 John T Houder,2 Nita A Limdi,6 Kelsey J Cook,7,8 Aniwaa Owusu Obeng,9 Natasha Petry,10 Sony Tuteja,11 Amanda R Elsey,2 Larisa H Cavallari,2 Kristin Wiisanen2 ...
Duong BQ +13 more
doaj
PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS
Архивъ внутренней медицины, 2018 The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment.
A. L. Khokhlov +7 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. [PDF]
PLoS ONE, 2011 CYP2D6 belongs to the cytochrome P450 superfamily of enzymes and plays an important role in the metabolism of 20-25% of clinically used drugs including antidepressants.
Rula Y Qumsieh +5 more
doaj +1 more source
Pharmaceutics, 2022 The cytochrome P450 2D6 (CYP2D6) genotype is the single most important determinant of CYP2D6 activity as well as interindividual and interpopulation variability in CYP2D6 activity.
Simeon Rüdesheim +6 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Beta‐adrenoreceptor blockers (beta‐blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group.
Ziyi Cai +10 more
wiley +1 more source
Potential role of CYP2D6 in the central nervous system [PDF]
, 2013 1. Cytochrome P450 2D6 (CYP2D6) is a pivotal enzyme responsible for a major drug oxidation polymorphism in human populations. Distribution of CYP2D6 in brain and its role in serotonin metabolism suggest that CYP2D6 may have a function in the central ...
Zhen, Yueying +12 more
core +1 more source
CYP2D6 polymorphism and its clinical implications [PDF]
, 2010 Artículo de InvestigaciónAbstract. CYP2D6 is the most important enzyme in the metabolism of drugs and is responsible for the metabolism of 25% of all drugs currently available on the market.
Lares Asseff, Ismael +1 more
core +2 more sources